Michelle H. Rich

Michelle H. Rich

Auto-generated profile, based on publicly available information

Michelle H. Rich

School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2015 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
EWElsie M. Williams
Elsie M. Williams
RLRory F. Little
Rory F. Little
AMAlexandra Mowday
Alexandra Mowday
MRMichelle H. Rich
Michelle H. Rich
JCJasmine V.E. Chan-Hyams
Jasmine V.E. Chan-Hyams
DADavid Ackerley
David Ackerley
This review examines the vast catalytic and therapeutic potential offered by type I (i.e. oxygen-insensitive) nitroreductase enzymes in partnership with nitroaromatic prodrugs, with particular focus on gene-directed enzyme prodrug therapy (GDEPT; a form of cancer gene therapy). Important first indications of this potential were demonstrated over 20 years ago, for the enzyme–prodrug pairing of Escherichia coli NfsB and CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide]. However, it has become apparent that both the enzyme and the prodrug in this prototypical pairing have limitations that have impeded their clinical progression. Recently, substantial advances have been made in the biodiscovery and engineering of superior nitroreductase variants, in particular development of elegant high-throughput screening capabilities to enable optimization of desirable activities via directed evolution. These advances in enzymology have been paralleled by advances in medicinal chemistry, leading to the development of second- and third-generation nitroaromatic prodrugs that offer substantial advantages over CB1954 for nitroreductase GDEPT, including greater dose-potency and enhanced ability of the activated metabolite(s) to exhibit a local bystander effect. In addition to forging substantial progress towards future clinical trials, this research is supporting other fields, most notably the development and improvement of targeted cellular ablation capabilities in small animal models, such as zebrafish, to enable cell-specific physiology or regeneration studies.

4 July 2014 in Protein Engineering, Design and Selection
Verified
Journal Article
Closed access
PDF file
JCJ.N. Copp
J.N. Copp
EWE.M. Williams
E.M. Williams
MRM.H. Rich
M.H. Rich
APAdam Patterson
Adam Patterson
JSJ.B. Smaill
J.B. Smaill
DADavid Ackerley
David Ackerley
Engineering of enzymes to more efficiently activate genotoxic prodrugs holds great potential for improving anticancer gene or antibody therapies. We report the development of a new, GFP-based, high-throughput screening platform to enable engineering of prodrug-activating enzymes by directed evolution. By fusing an inducible SOS promoter to an engineered GFP reporter gene, we were able to measure levels of DNA damage in intact Escherichia coli and separate cell populations by fluorescence activating cell sorting (FACS). In two FACS iterations, we were able to achieve a 90 000-fold enrichment of a functional prodrug-activating nitroreductase from a null library background.

13 November 2020 in eLife
Verified
Journal Article
Open access
KHKelsi R Hall
Kelsi R Hall
KRKatherine J Robins
Katherine J Robins
EWElsie M Williams
Elsie M Williams
MRMichelle H Rich
Michelle H Rich
MCMark Calcott
Mark Calcott
DADavid Ackerley
David Ackerley
Selection for a promiscuous enzyme activity provides substantial opportunity for competition between endogenous and newly-encountered substrates to influence the evolutionary trajectory, an aspect that is often overlooked in laboratory directed evolution studies. We selected the Escherichia coli nitro/quinone reductase NfsA for chloramphenicol detoxification by simultaneously randomising eight active-site residues and interrogating ~250,000,000 reconfigured variants. Analysis of every possible intermediate of the two best chloramphenicol reductases revealed complex epistatic interactions. In both cases, improved chloramphenicol detoxification was only observed after an R225 substitution that largely eliminated activity with endogenous quinones. Error-prone PCR mutagenesis reinforced the importance of R225 substitutions, found in 100% of selected variants. This strong activity trade-off demonstrates that endogenous cellular metabolites hold considerable potential to shape evolutionary outcomes. Unselected prodrug-converting activities were mostly unaffected, emphasising the importance of negative selection to effect enzyme specialisation, and offering an application for the evolved genes as dual-purpose selectable/counter-selectable markers.

12 August 2019 in Biochemistry
Verified
Journal Article
Closed access
EWElsie M. Williams
Elsie M. Williams
MRMichelle H. Rich
Michelle H. Rich
AMAlexandra Mowday
Alexandra Mowday
AAAmir Ashoorzadeh
Amir Ashoorzadeh
JCJanine N. Copp
Janine N. Copp
DADavid Ackerley
David Ackerley


17 October 2024 in Green Chemistry
Verified
Journal Article
Open access
PDF file
MBManuel Bruch
Manuel Bruch
JSJulián Eduardo Sánchez-Velandia
Julián Eduardo Sánchez-Velandia
JPJhonatan Rodriguez Pereira
Jhonatan Rodriguez Pereira
MRMichelle Rich
Michelle Rich
NPNicole Pearcy
Nicole Pearcy
MZMarcileia Zanatta
Marcileia Zanatta
From atmospheric CO 2 to green plastics, a sustainable journey.